LifeStance Health Gr Analyst Price Targets

Wall Street analyst price targets and consensus rating for LifeStance Health Gr (LFST).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

8Buy

2Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$11Upside to Avg. PT-6.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	Keybanc	Steve Dechert	PT Raise	Overweight	$13→$15
Sep 10, 2026	Barclays	Peter Warendorf	PT Raise	Overweight	$13→$15
Sep 9, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$13→$15
Aug 19, 2026	BTIG	David Larsen	PT Raise	Buy	$16→$18
Aug 14, 2026	JP Morgan	Lisa Gill	PT Raise	Neutral	$9→$13
Aug 7, 2026	BTIG	David Larsen	PT Raise	Buy	$15→$16
Jul 24, 2026	BTIG	David Larsen	PT Raise	Buy	$12→$15
Jul 21, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$11→$13
Jul 14, 2026	Barclays	Peter Warendorf	PT Raise	Overweight	$9→$13
Jul 13, 2026	Keybanc	Steve Dechert	PT Raise	Overweight	$11→$13
Jun 5, 2026	Goldman Sachs	Scott Fidel	Initiate	Buy→Neutral	$9
May 14, 2026	JP Morgan	Lisa Gill	PT Raise	Neutral	$8→$9
May 8, 2026	BTIG	David Larsen	PT Raise	Buy	$11→$12
Mar 6, 2026	Barclays	Peter Warendorf	PT Raise	Overweight	$8→$9
Feb 26, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$9→$10
Feb 26, 2026	UBS	Kevin Caliendo	PT Raise	Buy	$10→$12
Feb 26, 2026	Keybanc	Scott Schoenhaus	PT Raise	Overweight	$8→$9
Feb 2, 2026	BTIG	David Larsen	PT Raise	Buy	$10→$11
Dec 12, 2025	BTIG	David Larsen	PT Raise	Buy	$9→$10
Dec 9, 2025	Barclays	Peter Warendorf	Initiate	Overweight	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Keybanc Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

Keybanc analyst Steve Dechert maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $13 to $15.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

Barclays analyst Peter Warendorf maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $13 to $15.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on LifeStance Health Gr, Raises Price Target to $15

Canaccord Genuity analyst Richard Close maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $13 to $15.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $18

BTIG analyst David Larsen maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $16 to $18.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on LifeStance Health Gr, Raises Price Target to $13

JP Morgan analyst Lisa Gill maintains LifeStance Health Gr (NASDAQ:LFST) with a Neutral and raises the price target from $9 to $13.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $16

BTIG analyst David Larsen maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $15 to $16.

Benzinga Newsdesk

LifeStance Health Group Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

LifeStance Health Gr Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Keybanc Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

PRO
Barclays Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

PRO
Canaccord Genuity Maintains Buy on LifeStance Health Gr, Raises Price Target to $15

PRO
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $18

PRO
JP Morgan Maintains Neutral on LifeStance Health Gr, Raises Price Target to $13

PRO
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $16

People Also Watch

People Also Watch

LifeStance Health Group Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

LifeStance Health Gr Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROKeybanc Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

PROBarclays Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

PROCanaccord Genuity Maintains Buy on LifeStance Health Gr, Raises Price Target to $15

PROBTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $18

PROJP Morgan Maintains Neutral on LifeStance Health Gr, Raises Price Target to $13

PROBTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $16

People Also Watch

People Also Watch

PRO
Keybanc Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

PRO
Barclays Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15

PRO
Canaccord Genuity Maintains Buy on LifeStance Health Gr, Raises Price Target to $15

PRO
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $18

PRO
JP Morgan Maintains Neutral on LifeStance Health Gr, Raises Price Target to $13

PRO
BTIG Maintains Buy on LifeStance Health Gr, Raises Price Target to $16